AstraZeneca plc’s shock plunge is a buying opportunity for the brave

This could be the moment to buy AstraZeneca plc (LON: AZN) that you have been waiting for, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE: AZN) chief executive Pascal Soriot was always pursuing a high-risk, high-growth strategy, everybody knew that. Betting the farm on producing a string of lucrative new drug treatments was going to rattle nerves at some point.

Astra’s weaker

Yesterday was that point, with Astra’s share price plunging 15% after the failure of its new Mystic drug, designed as a first-line alternative to chemotherapy in stage IV lung cancer. I have seen this described as the most anticipated pharmaceutical industry clinical experiment this year, and it has ended badly. We warned you about Soriot’s high stakes game enough times and I said it was a strategy well worth pursuing. What choice did he have?

When Soriot was appointed CEO in October 2012 he inherited a seriously troubled company. The drug pipeline was depleting, key brands had lost exclusivity, cash-strapped governments were cutting health spending, and both revenues and profits were down sharply. At the time, investors could buy it for less than eight times earnings, on a yield of more than 6%.

Crestor of a wave

AstraZeneca looks in better shape today, even after yesterday’s crash. Its share price has climbed from 2,971p to 4,325p since his appointment, a rise of more than 45%. It is currently valued at 13.12 time earnings. This is still a great income play, yielding 5.09%. However, there are clearly underlying problems.

Loss of exclusivity of Crestor and Seroquel XR in the US is hurting, and was largely responsible for the 11% fall in product sales to $9.78bn. This was in line with expectations and is of course why Soriot was so keen to build up a new generation of treatments to replenish the old guard.

Profits up

AstraZeneca is hardly a one-trick pony either. As Soriot pointed out yesterday, it continues to deliver “transformative science across the pipeline, particularly in Oncology”. There are successes: lung cancer pill Tagrisso has significantly improved progression-free survival.

The company also confirmed a new partnership with Merck & Co to develop its Lynparza treatment for multiple cancer types and selumetinib for multiple indications including thyroid cancer, which Soriot called a “truly exciting step”. Also, while sales and revenues may have fallen, reported operating profit surged 37% to $1.84bn, boosted by the weaker pound, or 22% at constant currencies.

Farewell, Pascal?

Yet AstraZeneca suffered a major blow and there is plenty of uncertainty swirling around the company as a result. Some analysts have suggested that this could put the dividend at risk. Others say this makes the company ripe for a takeover. It was strong enough to fight off Pfizer’s $106bn bid in 2014, the next pursuer could find its target in a weakened state. Reports and rumours could quickly drive the share price back upwards. 

Finally, there are reports that Soriot may be set to leave the company for Israeli firm Teva. Perhaps this wouldn’t be such a disaster as he has given the company a fresh direction and a new face could take it on from here. AstraZeneca may look a little risky for a company with a market capitalisation of £54.74. Then again, it has done for the last five years. It is a buy, if a brave one.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

How much would I need to invest in income shares to earn £300 a month?

What kind of lump sum would be required to earn £300 a month by taking advantage of some of the…

Read more »

Investing For Beginners

Up 31% in a month, could this FTSE 250 stock be getting bought out?

Jon Smith takes a look at speculation that's pushing the share price of a FTSE 250 share higher and considers…

Read more »

Investing Articles

Here’s how I’d follow Warren Buffett to start building passive income in 2025

Ben McPoland highlights one FTSE 250 firm with a strong competitive edge that he thinks can continue rewarding investors with…

Read more »

Investing Articles

Burberry shares: undervalued FTSE gems that are ready to rocket?

Burberry shares soared at the beginning of the week as the takeover rumour mill went into overdrive. Is Paul Summers…

Read more »

US Stock

Here are the latest share price forecasts for S&P 500 giant Amazon

Amazon has generated monster gains for investors over the last decade. And Wall Street analysts believe the S&P 500 stock…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

2 high-yield FTSE 250 shares I’d buy today — and 1 that I’d avoid

UK markets have felt some volatility after last week’s Budget and the FTSE 250 was no stranger to it. Our…

Read more »

Investing Articles

3 reasons the Rolls-Royce share price could soar over the next decade

Sustainable aviation fuel, narrow-body aircraft, and small nuclear reactors could all keep the Rolls-Royce share price climbing over the next…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

Here’s how much income I’d get if I invested my entire £20k ISA in cheap BT shares

BT shares are on the up but still cheap, while the FTSE 100 telecoms stock offers a good yield too.…

Read more »